Answers are grounded in this paper and cite their sources.
Lactiplantibacillus (L.) plantarum 299v DSM 9843 is a probiotic strain that showed safety and properties potentially beneficial in managing irritable bowel syndrome (IBS). To systematically review and meta-analyze the effects of L. plantarum 299v in participants of randomized controlled trials (RCTs) with IBS. We searched PubMed/MEDLINE, Embase, Scopus, and the Cochrane Central Register of Controlled Trials. A meta-analysis was performed using a random-effects model, pooling the outcomes of abdominal pain, bloating/flatulence, constipation, global symptoms. The review protocol was registered in PROSPERO (registration number CRD420261322875). Six RCTs enrolling 527 adult patients with IBS were included. L. plantarum 299v significantly reduced abdominal pain scores (SMD = − 2.16; 95% CI − 3.59 to − 0.72; p = 0.003), abdominal pain severity (SMD = − 0.39; 95% CI − 0.67 to − 0.12; p = 0.005), daily abdominal pain frequency (SMD = − 0.66; 95% CI − 1.02 to − 0.30; p = 0.0004) compared with placebo. The improvement rates of abdominal pain (RR = 4.83; 95% CI 1.94–11.99; p = 0.0007), bloating/flatulence (RR = 1.96; 95% CI 1.06–3.61; p = 0.03) and global symptoms (RR = 4.69; 95% CI 1.52–14.45; p = 0.007) were significantly higher in the probiotic group. No significant effect was observed for constipation (RR = 1.39; 95% CI 0.32–6.11; p = 0.66). Meta-analytic evidence supports the capacity of L. plantarum 299v to relieve abdominal pain, bloating, flatulence, and general symptoms. The observed diet-dependent response underscores the need for future research to investigate combined probiotic dietary interventions.
No takes yet. Share an insight, caveat, or question.
Brindicci et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: